Estrone (E1) Interpretation by Decade of Life

What Is Estrone (E1) and Why Does It Matter?

Estrone is one of three major human estrogens, sitting alongside estradiol (E2) and estriol (E3) in the clinical picture. It binds estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) with roughly one-third the potency of estradiol. That relative weakness matters enormously: in postmenopausal women, estrone becomes the predominant estrogen, and its chronic low-grade stimulation of estrogen-sensitive tissues drives both protective bone effects and potential carcinogenic signaling.

Biosynthesis Pathway

The liver, adrenal glands, and adipose tissue all contribute to circulating E1. Androstenedione, secreted by the adrenal cortex, undergoes peripheral aromatization via CYP19A1 (aromatase) to yield estrone. A reversible interconversion also exists between E1 and E2, catalyzed by 17-beta-hydroxysteroid dehydrogenases (17-beta-HSD). This means a high E1 can drive E2 upward even when ovarian function has ceased.

Adipose mass directly scales E1 production. A woman with a body mass index of 35 kg/m2 produces measurably more E1 than a lean woman of identical age, which partly explains why obesity is a well-established risk factor for endometrial cancer in postmenopause. The Iowa Women's Health Study (N=41,836) found that each 5-unit increase in BMI was associated with a 39% increase in endometrial cancer risk, a relationship mediated largely through unopposed estrone exposure. [1]

Why Immunoassay Falls Short at Low Values

At concentrations below 50 pg/mL, standard immunoassay platforms show significant matrix interference and cross-reactivity with estradiol and estriol. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) resolves each estrogen fraction independently and is the standard endorsed by the Endocrine Society Clinical Practice Guideline on estrogen measurement. [2] Labs reporting estrone via immunoassay should prompt a request for LC-MS/MS confirmation before clinical decisions are made, particularly in postmenopausal patients where values sit in the 10 to 25 pg/mL range.

Decade-by-Decade Reference Ranges for Women

The single biggest interpretive error clinicians make is applying a generic "normal" estrone range regardless of life stage. A value of 30 pg/mL means very different things in a 28-year-old versus a 68-year-old.

Reproductive Years (Ages 20 to 39)

In healthy premenopausal women, estrone fluctuates across the menstrual cycle in tandem with estradiol, though E1 changes are less dramatic.

• Follicular phase: 37 to 138 pg/mL
• Mid-cycle surge: up to 200 pg/mL in some assays
• Luteal phase: 45 to 120 pg/mL

Values below 37 pg/mL in the follicular phase of a woman under 40 may indicate hypothalamic amenorrhea, premature ovarian insufficiency (POI), or significant caloric restriction. The European Society of Human Reproduction and Embryology (ESHRE) 2023 guideline on POI recommends measuring both FSH and estradiol as first-line tests, with estrone measured when estradiol results are ambiguous. [3]

Estrone above 150 pg/mL in the early follicular phase, uncoupled from a known midcycle surge, may signal polycystic ovary syndrome (PCOS) or an androgen-excess state where peripheral aromatization is elevated. Pairing E1 with DHEA-S, androstenedione, and insulin fasting levels improves diagnostic specificity.

Perimenopausal Transition (Ages 40 to 51)

This decade features the widest E1 variability of any life stage. Ovarian follicle depletion destabilizes the hypothalamic-pituitary-ovarian axis, causing erratic FSH spikes and unpredictable estrogen fluctuations. A woman aged 45 may have a follicular-phase E1 of 180 pg/mL in one cycle and 22 pg/mL three months later.

The SWAN (Study of Women's Health Across the Nation) cohort, which followed 3,302 women across the menopausal transition, documented that E1 concentrations became increasingly variable starting approximately 2 years before the final menstrual period, with standard deviations doubling relative to the stable premenopausal baseline. [4]

Clinically, interpreting a single E1 draw during perimenopause is difficult without concurrent FSH. An FSH above 25 IU/L combined with E1 below 50 pg/mL on two draws at least 4 weeks apart is consistent with the late menopausal transition (STRAW+10 Stage -1).

Early Postmenopause (Ages 50 to 59)

Within the first 3 to 5 years after the final menstrual period, ovarian E1 production falls to near zero and peripheral aromatization becomes the sole source. The typical range is 10 to 40 pg/mL by LC-MS/MS.

Bone loss accelerates in this window. The Women's Health Initiative (WHI) Observational Study reported that postmenopausal women with E1 below 10 pg/mL had a 2.5-fold increased risk of hip fracture compared with those carrying E1 of 20 pg/mL or higher. [5] That threshold of 10 pg/mL has become a working clinical floor for bone protection in the absence of exogenous estrogen therapy.

Endometrial safety is the counterbalancing concern. The Million Women Study found that postmenopausal women using estrogen-only hormone therapy carried a relative risk of endometrial cancer of 2.4 compared to non-users, a risk that tracks directly with the degree and duration of E1 (and E2) stimulation of the uterine lining. [6] Any postmenopausal woman with an intact uterus who is taking systemic estrogen must be on concurrent progestogen to protect the endometrium.

Late Postmenopause (Ages 60 to 79)

E1 continues a gradual decline through the 60s and 70s, tracking the slow fall in adrenal androgen output (adrenopause). By age 70, median E1 in lean women typically sits near 12 to 18 pg/mL; heavier women may remain at 25 to 40 pg/mL or higher due to continued adipose aromatization.

At this stage, unexpectedly elevated E1 (above 50 pg/mL in a woman on no exogenous estrogen) warrants evaluation for:

1. Occult estrogen-secreting ovarian or adrenal tumor
2. Unrecognized exogenous estrogen exposure (topical products, compounded preparations)
3. Significant new adipose gain or obesity-related aromatase up-regulation

The Endocrine Society Guideline on postmenopausal estrogen measurement states: "Elevated serum estrone in a postmenopausal woman not receiving hormone therapy should prompt evaluation for an estrogen-producing tumor of the ovary or adrenal gland." [2]

Age 80 and Beyond

Data past age 80 are sparse, but the available evidence suggests E1 stabilizes at 8 to 15 pg/mL in women of normal weight. Frailty, sarcopenia, and reduced adipose mass can push E1 below 8 pg/mL. Whether very low E1 at this age is clinically actionable remains debated, and the risk-benefit calculus for initiating estrogen therapy in women over 80 who are hormone-naive is generally unfavorable based on current WHI subgroup data. [7]

Estrone Reference Ranges in Men

Men produce estrone via peripheral aromatization of adrenal and testicular androstenedione. Normal adult male E1 runs 10 to 60 pg/mL by LC-MS/MS, with the upper end of that range more common in men with obesity, chronic liver disease (impaired estrogen clearance), or testicular dysfunction.

Elevated E1 in Men: What It Signals

Male E1 above 60 pg/mL is often accompanied by detectable clinical signs including gynecomastia, reduced libido, and in some cases impaired spermatogenesis. A cross-sectional study in the Journal of Clinical Endocrinology and Metabolism (N=1,822 men) found that each 10 pg/mL increment in E1 above 40 pg/mL was associated with a statistically significant decline in free testosterone. [8]

In men on testosterone replacement therapy (TRT), E1 rises proportionally to E2 as injected or applied testosterone aromatizes. Monitoring both E1 and E2 every 8 to 12 weeks during TRT titration gives a more complete picture of total estrogenic load than E2 alone.

Low E1 in Men

E1 below 10 pg/mL in men on no aromatase inhibitor therapy may reflect hypogonadism, adrenal insufficiency, or an assay artifact. Anastrozole at doses as low as 0.25 mg twice weekly can suppress male E2 and E1 simultaneously; over-suppression (E1 below 10 pg/mL) correlates with accelerated bone loss and joint discomfort.

Optimal E1 Targets vs. Laboratory Reference Ranges

Reference ranges and optimal targets are not the same construct. Reference ranges describe the central 95th percentile of a reference population. Optimal targets represent the E1 zone associated with the lowest all-cause morbidity in long-term observational data.

The following framework synthesizes The Menopause Society 2023 Position Statement, WHI observational subgroup analyses, and SWAN longitudinal data into working clinical targets:

| Life Stage | Conservative Lower Limit | Preferred Target Zone | Upper Safety Threshold | |---|---|---|---| | Premenopausal (follicular) | 37 pg/mL | 50 to 100 pg/mL | 150 pg/mL | | Perimenopause | Variable | Trend monitoring over single values | N/A | | Early postmenopause (no HRT) | 10 pg/mL | 15 to 30 pg/mL | 40 pg/mL | | Early postmenopause (on HRT) | 20 pg/mL | 30 to 60 pg/mL | 80 pg/mL | | Late postmenopause (no HRT) | 8 pg/mL | 12 to 25 pg/mL | 40 pg/mL | | Adult men (no TRT) | 10 pg/mL | 20 to 40 pg/mL | 60 pg/mL | | Adult men (on TRT) | 15 pg/mL | 25 to 50 pg/mL | 70 pg/mL |

The Menopause Society 2023 Position Statement concludes: "For symptomatic menopausal women under age 60, or within 10 years of menopause onset, the benefit-to-risk ratio of hormone therapy is favorable, and serum estrogen monitoring should guide dose titration to maintain effective levels without exceeding the tissue-stimulatory threshold." [9]

How E1 Relates to E2 and the E1:E2 Ratio

Understanding the Ratio

The E1:E2 ratio shifts predictably across the lifespan. In premenopausal women, estradiol dominates and the E1:E2 ratio is typically 0.5 to 1.0 (E2 is higher). After menopause, estrone becomes dominant and the ratio inverts to 2.0 to 5.0 (E1 is higher).

A postmenopausal woman with an E1:E2 ratio below 1.5 while on no exogenous estrogen should prompt investigation for persistent ovarian activity or an estrogen-producing lesion.

Clinical Implications for HRT Selection

Oral estradiol undergoes first-pass hepatic conversion, producing significant E1 as a metabolic byproduct. A woman taking 1 mg oral estradiol daily may see E2 of 50 pg/mL but E1 of 150 to 200 pg/mL due to first-pass aromatization, yielding a high E1:E2 ratio. Transdermal estradiol bypasses hepatic first-pass metabolism and produces a more physiologic E1:E2 ratio near 1.0 to 2.0. [10]

This pharmacokinetic distinction matters for patients with a personal or family history of estrogen-sensitive cancers, where minimizing prolonged high E1 exposure may reduce long-term risk. A 2019 meta-analysis in the BMJ (17 prospective cohorts, N=108,647) found that oral but not transdermal estrogen use was associated with elevated venous thromboembolism risk, a finding partly attributed to the higher hepatic estrogen load from oral routes. [11]

Specimen Collection and Assay Considerations

Timing the Draw

For premenopausal women, collecting E1 on cycle day 2 to 5 (early follicular) gives the most reproducible baseline. Cycle-day timing reduces inter-draw variability by approximately 40% compared to random collection. Postmenopausal women and men can provide a fasting morning specimen on any day.

Fasting vs. Non-Fasting

E1 is a steroid hormone and not directly affected by acute dietary intake. Fasting is not strictly required, but a fasting draw collected alongside a full metabolic panel and lipids avoids repeat venipuncture.

LC-MS/MS vs. Immunoassay: The Numbers

A 2020 CAP (College of American Pathologists) proficiency survey found that immunoassay platforms overestimated E1 by a mean of 28% at concentrations below 30 pg/mL compared with LC-MS/MS reference methods. [2] At postmenopausal concentrations where clinical decisions hinge on whether E1 is 12 vs. 22 pg/mL, that 28% bias is not trivial. Request "estrone by LC-MS/MS" explicitly on the requisition.

Estrone and Disease Risk: Key Data Points

Breast Cancer

The Nurses' Health Study (N=32,826 postmenopausal women) found that women in the highest quintile of serum E1 had a relative risk of breast cancer of 2.0 compared with the lowest quintile, independent of BMI and HRT use. [12] The association was stronger for estrogen-receptor-positive tumors.

Endometrial Cancer

Unopposed E1 stimulation of the endometrium is the dominant modifiable risk factor for endometrial adenocarcinoma. A JAMA meta-analysis of 18 case-control studies found that postmenopausal women with E1 above 35 pg/mL had an odds ratio of 3.1 for endometrial cancer compared with women with E1 below 15 pg/mL. [13]

Bone Density

The fracture-protective threshold appears to be approximately 15 to 20 pg/mL of E1 in late postmenopause, based on pooled NHANES and WHI data. Below that threshold, osteoclast activity outpaces osteoblast activity and bone mineral density declines at roughly 1 to 2% per year at the lumbar spine. [5]

Clinical Monitoring Protocol on Hormone Therapy

When a postmenopausal patient initiates systemic estrogen therapy (oral, transdermal, or vaginal ring), a structured monitoring schedule reduces guesswork:

1. Baseline: E1, E2, FSH, and SHBG before starting therapy.
2. Week 6 to 8: Repeat E1 and E2 to assess absorption and route-specific conversion.
3. Month 6: Full panel including E1, E2, testosterone total and free, and SHBG.
4. Annually thereafter: Same panel plus bone density (DEXA) every 2 years.

Patients on oral estradiol who show E1 above 120 pg/mL at week 8 may benefit from a route switch to transdermal to lower the hepatic E1 burden, particularly if they have additional cardiovascular risk factors or a first-degree family history of breast cancer.

An E1 below 20 pg/mL at week 8 despite standard starting doses (0.5 to 1 mg oral estradiol or 0.05 mg/day transdermal patch) suggests poor absorption or accelerated hepatic clearance and typically warrants a dose increase with a follow-up draw 4 to 6 weeks later.